# OnCo record klrc1 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/klrc1/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "klrc1" ;
  schema:name "NKG2A (KLRC1)"@en ;
  schema:alternateName "NKG2A"@en, "NKG2-A"@en, "CD159a"@en, "killer cell lectin like receptor C1"@en, "KLRC1" ;
  schema:description "NKG2A is the brake on NK cells and some killer T cells that is pressed by HLA-E, a molecule tumours raise to look like self. Monalizumab blocks it and is in phase 3 with durvalumab in lung cancer and with cetuximab in head and neck cancer."@en ;
  schema:url <https://onco.cc/targets/klrc1/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6374>, <https://www.uniprot.org/uniprotkb/P26715/entry>, <https://www.ncbi.nlm.nih.gov/gene/3821>, <https://clinicaltrials.gov/study/NCT05221840> ;
  onco:tag "checkpoint-map" ;
  onco:targetClass "checkpoint" ;
  schema:sameAs <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6374>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134545>, <https://www.uniprot.org/uniprotkb/P26715/entry>, <https://www.ncbi.nlm.nih.gov/gene/3821> ;
  onco:related <https://onco.cc/targets/hla-e/>, <https://onco.cc/terms/nk-cell/>, <https://onco.cc/drugs/durvalumab/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/monalizumab/> ;
  onco:pathways <https://onco.cc/pathways/cancer-immunity-cycle/> .